HRP20210357T1 - Stabilna i topljiva protutijela koja inhibiraju tnf - Google Patents

Stabilna i topljiva protutijela koja inhibiraju tnf Download PDF

Info

Publication number
HRP20210357T1
HRP20210357T1 HRP20210357TT HRP20210357T HRP20210357T1 HR P20210357 T1 HRP20210357 T1 HR P20210357T1 HR P20210357T T HRP20210357T T HR P20210357TT HR P20210357 T HRP20210357 T HR P20210357T HR P20210357 T1 HRP20210357 T1 HR P20210357T1
Authority
HR
Croatia
Prior art keywords
disease
syndrome
seq
pain
cdr
Prior art date
Application number
HRP20210357TT
Other languages
English (en)
Inventor
Leonardo Borras
Tea Gunde
David Urech
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41100661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20210357(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20210357T1 publication Critical patent/HRP20210357T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)

Claims (16)

1. Imunovezno sredstvo koje se specifično veže na ljudski TNFα, naznačeno time, da imunovezno sredstvo sadrži: (i) slijed varijabilnog okvira ljudskog teškog lanca i CDR H1, CDR H2 i CDR H3 sljedove koji potječu od zečjeg imunoveznog sredstva, pri čemu ljudski okvir varijabilne regije ljudskog teškog lanca ima najmanje 90% identičnosti sa SEQ ID NO: 89 ili SEQ ID NO: 90, gdje okvir varijabilne regije teškog lanca sadrži jednu ili više od sljedećih aminokiselina: treonin (T) na položaju 24, valin (V) na položaju 25, alanin (A) ili glicin (G) na položaju 56, lizin (K) na položaju 82, treonin (T) na položaju 84, valin (V) na položaju 89, i arginin (R) na položaju 108 (AHo numeriranje); i (ii) slijed varijabilnog okvira ljudskog lakog lanca i CDR L1, CDR L2 i CDR L3 sljedove koji potječu od zečjeg imunoveznog sredstva, gdje okvir varijabilne regije ljudskog lakog lanca ima najmanje 90% identičnosti sa SEQ ID NO: 91, pri čemu su sljedovi navedenih CDR H1, CDR H2, CDR H3, CDR L1, CDR L2, i CDR L3 koji potječu od zečjeg imunoveznog sredstva sljedeći: SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37 i SEQ ID NO: 38, odgovarajućim redom.
2. Imunovezno sredstvo prema patentnom zahtjevu 1, naznačeno time, da imunovezno sredstvo sadrži supstituciju koja povećava topivost na amino položajima 12, 103 i 144 (AHo numeriranje) teškog lanca.
3. Imunovezno sredstvo prema patentnom zahtjevu 2, naznačeno time, da je supstitucija koja povećava topivost odabrana iz skupine koju čine: (a) Serin (S) na položaju 12; (b) Treonin (T) na položaju 103; i (c) Treonin (T) na položaju 144.
4. Imunovezno sredstvo prema patentnom zahtjevu 1, naznačeno time, da sadrži: varijabilnu regiju teškog lanca (VH) koja posjeduje slijed s najmanje 90% identičnosti sa SEQ ID NO:77 ili SEQ ID NO:79, i varijabilnu regiju lakog lanca (VL) koja je najmanje 90% identična sa SEQ ID NO:78 ili SEQ ID NO:80.
5. Imunovezno sredstvo prema bilo kojem od patentnih zahtjeva 1-4, naznačeno time, da je protutijelo, scFv, Fab ili Dab.
6. Pripravak, naznačen time, da sadrži imunovezno sredstvo prema bilo kojem od patentnih zahtjeva 1-4 i farmaceutski prihvatljiv nosač.
7. Pripravak prema patentnom zahtjevu 6, naznačen time, da je formuliran za topikalnu, oralnu, nazalnu, rektalnu ili parenteralnu primjenu.
8. Izolirana molekula nukleinske kiseline, naznačena time, da kodira varijabilnu regiju teškog lanca (VH) ili varijabilnu regiju lakog lanca (VL) prema bilo kojem od patentnih zahtjeva 1-4.
9. Ekspresijski vektor, naznačen time, da sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 8.
10. Stanica domaćina, naznačena time, da sadrži ekspresijski vektor prema patentnom zahtjevu 9.
11. Pripravak koji sadrži imunovezno sredstvo prema bilo kojem od patentnih zahtjeva 1-4, naznačen time, da je za uporabu u liječenju ili prevenciji ljudske bolesti posredovane s TNFα, pri čemu je bolest posredovana s TNFα odabrana iz skupine koju čine: općenita kronična ili autoimuna upalna stanja, općeniti imunološki posredovani upalni poremećaji, upalna bolest središnjeg živčanog sustava, upalne bolesti koje utječu na oko, zglob, kožu, membrane sluznice, središnji živčani sustav, gastrointestinalni trakt, mokraćni trakt ili pluća, općenita stanja uveitisa, retinitis, HLA-B27+ uveitis, Behcetova bolest, sindrom suhog oka, glaukom, Sjögrenov sindrom, dijabetes melitus, dijabetička neuropatija, inzulinska rezistencija, općenita stanja artritisa, reumatoidni artritis, osteoartritis, reaktivni artritis i Reiterov sindrom, mladenački artritis, ankilozirajući spondilitis, multipla skleroza, Guillain-Barreov sindrom, miastenija gravis, amiotrofična lateralna skleroza, sarkoidoza, glomerulonefritis, kronična bolest bubrega, cistitis, psorijaza, psorijatični artritis, hidradenitis suppurativa, panikulitis, gangrenozna pioderma, SAPHO sindrom, akne, Sweetov sidrom, pemfigus, Crohnova bolest, ulcerozni kolitis, bronhijalna astma, pneumonitis zbog preosjetljivosti, općenite alergije, alergijski rinitis, alergijski sinusitis, kronična opstruktivna plućna bolest (KOPB), fibroza pluća, Wegenerova granulomatoza, Kawasakijev sindrom, arteritis divovskih stanica, Churg-Straussov vaskulitis, nodozni poliarteritis, opekline, bolest presatka protiv domaćina, reakcije domaćina protiv presatka, epizode odbacivanja nakon transplantacije organa ili koštane srži, općenita sistemska i lokalna stanja vaskulitisa, sistemski i diskoidni eritematozni lupus, polimiozitis i dermatomiozitis, sklerodermija, preeklampsija, akutni i kronični pankreatitis, virusni hepatitis, alkoholni hepatitis, upala nakon kirurške operacije, operacije zgloba, operacije zglobne strukture, oralne ili zubne operacije, minimalno invazivnih kardiovaskularnih postupaka, laparoskopskih ili endoskopskih intraabdominalnih i ginekoloških zahvata, endoskopskih uroloških zahvata, ili općenito perioperativnih upala, Alzheimerova bolest, Parkinsonova bolest, Huntingtonova bolest, Bellova paraliza, Creutzfeld -Jakobova bolest, osteoliza zbog raka, upala zbog raka, bol zbog raka, kaheksija zbog raka, metastaze u kostima, akutni i kronični oblici boli, nociceptivni ili neuropatski oblici boli, išijas, bolovi u križima, sindrom karpalnog kanala, složeni regionalni sindrom boli (CRPS), giht, postherpetična neuralgija, fibromialgija, lokalna stanja boli, kronični bolni sindromi zbog metastatskog tumora, dismenoreja, bakterijska, virusna ili gljivična sepsa, tuberkuloza, AIDS, ateroskleroza, bolest koronarnih arterija, hipertenzija, dislipidemija, srčana insuficijencija i kronično zatajenje srca.
12. Uporaba imunoveznog sredstva prema bilo kojem od patentnih zahtjeva 1-4, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju ljudske bolesti posredovane s TNFα.
13. Imunovezno sredstvo prema bilo kojem od patentnih zahtjeva 1-4, naznačeno time, da je za uporabu u liječenju ili prevenciji ljudske bolesti posredovane s TNFα.
14. Uporaba u skladu s patentnim zahtjevom 12, ili imunovezno sredstvo za uporabu u skladu s patentnim zahtjevom 13, naznačeni time, da je bolest posredovana s TNFα odabrana iz skupine koju čine: općenita kronična ili autoimuna upalna stanja, općeniti imunološki posredovani upalni poremećaji, upalna bolest središnjeg živčanog sustava, upalne bolesti koje utječu na oko, zglob, kožu, membrane sluznice, središnji živčani sustav, gastrointestinalni trakt, mokraćni trakt ili pluća, općenita stanja uveitisa, retinitis, HLA-B27+ uveitis, Behcetova bolest, sindrom suhog oka, glaukom, Sjögrenov sindrom, dijabetes melitus, dijabetička neuropatija, inzulinska rezistencija, općenita stanja artritisa, reumatoidni artritis, osteoartritis, reaktivni artritis i Reiterov sindrom, mladenački artritis, ankilozirajući spondilitis, multipla skleroza, Guillain-Barreov sindrom, miastenija gravis, amiotrofična lateralna skleroza, sarkoidoza, glomerulonefritis, kronična bolest bubrega, cistitis, psorijaza, psorijatični artritis, hidradenitis suppurativa, panikulitis, gangrenozna pioderma, SAPHO sindrom, akne, Sweetov sidrom, pemfigus, Crohnova bolest, ulcerozni kolitis, bronhijalna astma, pneumonitis zbog preosjetljivosti, općenite alergije, alergijski rinitis, alergijski sinusitis, kronična opstruktivna plućna bolest (KOPB), fibroza pluća, Wegenerova granulomatoza, Kawasakijev sindrom, arteritis divovskih stanica, Churg-Straussov vaskulitis, nodozni poliarteritis, opekline, bolest presatka protiv domaćina, reakcije domaćina protiv presatka, epizode odbacivanja nakon transplantacije organa ili koštane srži, općenita sistemska i lokalna stanja vaskulitisa, sistemski i diskoidni eritematozni lupus, polimiozitis i dermatomiozitis, sklerodermija, preeklampsija, akutni i kronični pankreatitis, virusni hepatitis, alkoholni hepatitis, upala nakon kirurške operacije, operacije zgloba, operacije zglobne strukture, oralne ili zubne operacije, minimalno invazivnih kardiovaskularnih postupaka, laparoskopskih ili endoskopskih intraabdominalnih i ginekoloških zahvata, endoskopskih uroloških zahvata, ili općenito perioperativnih upala, Alzheimerova bolest, Parkinsonova bolest, Huntingtonova bolest, Bellova paraliza, Creutzfeld -Jakobova bolest, osteoliza zbog raka, upala zbog raka, bol zbog raka, kaheksija zbog raka, metastaze u kostima, akutni i kronični oblici boli, nociceptivni ili neuropatski oblici boli, išijas, bolovi u križima, sindrom karpalnog kanala, složeni regionalni sindrom boli (CRPS), giht, postherpetična neuralgija, fibromialgija, lokalna stanja boli, kronični bolni sindromi zbog metastatskog tumora, dismenoreja, bakterijska, virusna ili gljivična sepsa, tuberkuloza, AIDS, ateroskleroza, bolest koronarnih arterija, hipertenzija, dislipidemija, srčana insuficijencija i kronično zatajenje srca.
15. Imunovezno sredstvo prema bilo kojem od patentnih zahtjeva 1-4, naznačeno time, da je za uporabu kao lijek.
16. Imunovezno sredstvo za uporabu prema patentnom zahtjevu 15, naznačeno time, da je za primjenu intramuskularnim, intraperitonealnim, intracerobrospinalnim, supkutanim, intraartikularnim, intrasinovijalnim, intratekalnim, oralnim, topikalnim ili inhalacijskim putem.
HRP20210357TT 2008-06-25 2021-03-02 Stabilna i topljiva protutijela koja inhibiraju tnf HRP20210357T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US7564008P 2008-06-25 2008-06-25
US7569208P 2008-06-25 2008-06-25
US7569708P 2008-06-25 2008-06-25
US7595608P 2008-06-26 2008-06-26
US15504109P 2009-02-24 2009-02-24
EP18177227.8A EP3444274B1 (en) 2008-06-25 2009-06-25 Stable and soluble antibodies inhibiting tnf

Publications (1)

Publication Number Publication Date
HRP20210357T1 true HRP20210357T1 (hr) 2021-04-16

Family

ID=41100661

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210357TT HRP20210357T1 (hr) 2008-06-25 2021-03-02 Stabilna i topljiva protutijela koja inhibiraju tnf

Country Status (23)

Country Link
US (4) US8673310B2 (hr)
EP (3) EP3444274B1 (hr)
JP (4) JP6100463B2 (hr)
KR (5) KR101893010B1 (hr)
CN (2) CN107936117B (hr)
AU (1) AU2009264564B2 (hr)
BR (1) BRPI0914319B8 (hr)
CA (1) CA2727992C (hr)
CL (1) CL2010001543A1 (hr)
CY (1) CY1123978T1 (hr)
DK (2) DK2307457T4 (hr)
ES (2) ES2861592T3 (hr)
HR (1) HRP20210357T1 (hr)
HU (2) HUE039692T2 (hr)
LT (1) LT3444274T (hr)
MX (2) MX345039B (hr)
PH (1) PH12014501962B1 (hr)
PL (2) PL3444274T3 (hr)
PT (2) PT2307457T (hr)
RU (4) RU2653753C1 (hr)
SI (2) SI3444274T1 (hr)
WO (1) WO2009155723A2 (hr)
ZA (2) ZA201008593B (hr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102007492B1 (ko) 2008-06-25 2019-08-05 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
PT2307457T (pt) * 2008-06-25 2018-10-16 Esbatech Alcon Biomed Res Unit Anticorpos estáveis e solúveis que inibem o tnf
KR20110031373A (ko) 2008-07-10 2011-03-25 에스바테크, 언 알콘 바이오메디칼 리서치 유닛 엘엘씨 마크로분자 전달을 증강하는 방법 및 조성물
MX2011007049A (es) 2009-02-24 2011-08-03 Esbatech Alcon Biomed Res Unit Metodos para identificar inmunoligadores de los antegenos de la superficie celular.
EP3498731A1 (en) * 2009-12-23 2019-06-19 ESBATech, an Alcon Biomedical Research Unit LLC Method for decreasing immunogenicity
RU2535033C2 (ru) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Лекарственное средство и способ профилактики инфицирования вич, профилактики и лечения заболеваний, вызываемых вич или ассоциированных с вич, в том числе спида
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
AU2016277637B2 (en) * 2010-10-22 2018-11-08 Novartis Ag Stable and soluble antibodies
AU2013203189B2 (en) * 2010-10-22 2014-12-11 Novartis Ag Stable and soluble antibodies
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
EP2683404A4 (en) * 2011-03-07 2014-09-10 Univ Tokushima METHOD FOR TREATING AMYOTROPHER LATERAL SCLEROSIS
CN109608543A (zh) * 2011-10-20 2019-04-12 艾斯巴技术-诺华有限责任公司 稳定的多抗原结合抗体
ES2731757T3 (es) * 2012-03-20 2019-11-18 Biogen Ma Inc Anticuerpos neutralizantes de JCV
US9567391B2 (en) 2012-03-20 2017-02-14 Biogen Ma Inc. JCV neutralizing antibodies
CA3202536A1 (en) 2012-05-10 2013-11-14 Bioatla, Llc Multi-specific monoclonal antibodies
EP2931750B8 (en) 2012-12-17 2021-11-03 Cell Medica Inc. Antibodies against il-1 beta
AU2013378628A1 (en) * 2013-02-15 2015-06-11 Esbatech - A Novartis Company Llc Acceptor framework for CDR grafting
CN113943366A (zh) 2013-06-26 2022-01-18 努玛医疗技术有限公司 新型抗体框架
EP3122777B1 (en) * 2014-03-26 2020-12-23 Cell Medica Switzerland AG Binding members to tnf alpha
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
CN105727285B (zh) * 2014-12-10 2018-06-19 信达生物制药(苏州)有限公司 一种单克隆抗体在治疗神经退行性疾病中的应用
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
DK3219727T3 (da) 2016-03-17 2021-01-04 Tillotts Pharma Ag Anti-THF-alpha-antistoffer og funktionelle fragmenter deraf
MA43716A (fr) 2016-03-17 2018-11-28 Numab Innovation Ag Anticorps anti-tnf et fragments fonctionnels de ceux-ci
CN108884156B (zh) 2016-03-17 2021-10-01 努玛创新有限公司 抗TNFα抗体及其功能片段
PL3219726T3 (pl) * 2016-03-17 2021-07-19 Tillotts Pharma Ag Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty
KR102571700B1 (ko) 2016-03-17 2023-08-29 누맙 세러퓨틱스 아게 항TNFα 항체 및 이의 기능성 단편
EP3472203A1 (en) 2016-06-20 2019-04-24 Novartis AG Methods of treating dry eye disease using tnf alpha antagonists
WO2018111328A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of tnf inhibitors at the site of gastrointestinal tract disease
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP4424707A2 (en) * 2017-09-19 2024-09-04 Tillotts Pharma AG Antibody variants
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
EP3459527B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
AU2018365880A1 (en) * 2017-11-07 2020-05-28 The Board Of Regents Of The University Of Texas System Targeting LILRB4 with car-T or car-NK cells in the treatment of cancer
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
CN113194993A (zh) 2018-12-18 2021-07-30 诺华股份有限公司 含高浓度抗vegf抗体的蛋白质溶液配制品
AU2020215795A1 (en) 2019-01-31 2021-07-29 Numab Therapeutics AG Multispecific antibodies having specificity for TNFA and IL-17A, antibodies targeting IL-17A, and methods of use thereof
JP2023512951A (ja) 2020-01-23 2023-03-30 ジェネクシン・インコーポレイテッド Ｐｄ－ｌ１タンパク質が含まれた融合タンパク質およびその用途
WO2022174378A1 (zh) * 2021-02-19 2022-08-25 骏运投资有限公司 痘苗病毒致炎兔皮提取物治疗神经系统脱髓鞘疾病的用途
TW202321311A (zh) * 2021-08-02 2023-06-01 日商諾伊爾免疫生物科技股份有限公司 與scFv等之連接子結合的抗體
WO2024200722A1 (en) 2023-03-28 2024-10-03 Tillotts Pharma Ag Solid oral dosage form comprising antibodies for sustained release in the lower gastrointestinal tract

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5147638A (en) 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5644034A (en) 1989-08-07 1997-07-01 Peptide Technology Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
CA2126967A1 (en) 1992-11-04 1994-05-11 Anna M. Wu Novel antibody construct
DE122009000074I1 (de) 1993-03-05 2011-12-01 Bayer Healthcare Ag Humane monoklonale anti-TNF alpha Antikorper.
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
NZ512006A (en) 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US6905668B1 (en) 1998-09-25 2005-06-14 Tokyo Gas Company Limited Diagnostic agents for pancreatic exocrine function
US6470213B1 (en) * 1999-03-30 2002-10-22 Kenneth A. Alley Implantable medical device
DK1242457T3 (da) 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
US20040220388A1 (en) 2000-06-30 2004-11-04 Nico Mertens Novel heterodimeric fusion proteins
SG97908A1 (en) 2000-08-03 2003-08-20 Inst Data Storage A method and apparatus for load/unload testing of disk drives
DK1506236T3 (da) * 2002-05-22 2013-03-04 Esbatech A Novartis Co Llc Immunglobulin-frameworks, der udviser forbedret stabilitet i det intracellulære miljø og fremgangsmåder til identifikation deraf
AU2003264009A1 (en) 2002-08-15 2004-03-03 Epitomics, Inc. Humanized rabbit antibodies
DE10314412A1 (de) 2003-03-28 2004-10-14 Genovac Ag Genetische Immunisierung mit multiplen Expressionskonstrukten zur Herstellung von monoklonalen Antikörpern
US20050048578A1 (en) 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
CN100415765C (zh) 2003-08-07 2008-09-03 宜康公司 兔单克隆抗体的人源化方法
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
WO2005049597A1 (ja) 2003-11-20 2005-06-02 Mitsubishi Gas Chemical Company, Inc. 液状シクロヘキサントリカルボン酸無水物
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US20080003617A1 (en) 2004-12-20 2008-01-03 Xiaomin Fan Methods for the identification and the isolation of epitope specific antibodies
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
KR101457223B1 (ko) * 2005-06-07 2014-11-04 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 억제하는 안정적이고 가용성인 항체
JP5196654B2 (ja) 2005-06-20 2013-05-15 ジェネンテック， インコーポレイテッド 腫瘍の診断と治療のための組成物と方法
US7429487B2 (en) 2005-07-05 2008-09-30 Epitomics, Inc. Fusion partner for production of monoclonal rabbit antibodies
GB0520436D0 (en) 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
AU2006300951A1 (en) 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
NZ572248A (en) 2006-04-28 2011-08-26 Delenex Therapeutics Ag Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
EP2447282B1 (en) 2006-05-30 2016-01-27 Genentech, Inc. Anti-CD22 Antibodies, their Immunoconjugates and uses thereof
WO2008004834A1 (en) 2006-07-06 2008-01-10 Isu Abxis Co., Ltd Humanized monoclonal antibody highly binding to epidermal growth factor receptor, egf receptor
RU2438708C2 (ru) † 2006-07-10 2012-01-10 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк ScFv-АНТИТЕЛА, КОТОРЫЕ ПРОХОДЯТ ЧЕРЕЗ ЭПИТЕЛИАЛЬНЫЙ И/ИЛИ ЭНДОТЕЛИАЛЬНЫЙ СЛОИ
AU2007323925A1 (en) 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
EP2118138A1 (en) 2007-03-12 2009-11-18 Esbatech AG Sequence based engineering and optimization of single chain antibodies
WO2008144757A1 (en) 2007-05-21 2008-11-27 Alder Biopharmaceuticals, Inc. Novel rabbit antibody humanization methods and humanized rabbit antibodies
MX2009013328A (es) 2007-06-25 2010-06-02 Esbatech An Alcon Biomedical R Metodos para modificar anticuerpos, y anticuerpos modificados con propiedades funcionales mejoradas.
RU2010102064A (ru) 2007-06-25 2011-07-27 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк (Ch) Способ конструирования, основанный на определении последовательностей, способ оптимизации одноцепочечных антител
EP3216803B1 (en) 2008-06-25 2020-03-11 Novartis Ag Stable and soluble antibodies inhibiting vegf
PT2307457T (pt) * 2008-06-25 2018-10-16 Esbatech Alcon Biomed Res Unit Anticorpos estáveis e solúveis que inibem o tnf
ES2884117T3 (es) 2008-06-25 2021-12-10 Novartis Ag Optimización de la solubilidad de inmunoaglutinantes
KR102007492B1 (ko) 2008-06-25 2019-08-05 에스바테크 - 어 노바티스 컴파니 엘엘씨 보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
KR20110031373A (ko) * 2008-07-10 2011-03-25 에스바테크, 언 알콘 바이오메디칼 리서치 유닛 엘엘씨 마크로분자 전달을 증강하는 방법 및 조성물
MX2011007049A (es) * 2009-02-24 2011-08-03 Esbatech Alcon Biomed Res Unit Metodos para identificar inmunoligadores de los antegenos de la superficie celular.
EP3498731A1 (en) * 2009-12-23 2019-06-19 ESBATech, an Alcon Biomedical Research Unit LLC Method for decreasing immunogenicity
EP3122777B1 (en) * 2014-03-26 2020-12-23 Cell Medica Switzerland AG Binding members to tnf alpha
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US11326182B2 (en) * 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2019175727A1 (en) 2018-03-16 2019-09-19 Novartis Ag Methods for treating ocular diseases
CN113194993A (zh) 2018-12-18 2021-07-30 诺华股份有限公司 含高浓度抗vegf抗体的蛋白质溶液配制品

Also Published As

Publication number Publication date
EP3858854A1 (en) 2021-08-04
DK2307457T4 (da) 2022-08-22
PT3444274T (pt) 2021-03-17
BRPI0914319B1 (pt) 2020-09-29
JP2019195342A (ja) 2019-11-14
LT3444274T (lt) 2021-03-25
JP2011525358A (ja) 2011-09-22
ZA201308787B (en) 2016-08-31
DK2307457T3 (en) 2018-09-17
BRPI0914319A2 (pt) 2015-10-13
KR20180097792A (ko) 2018-08-31
CN102076716A (zh) 2011-05-25
RU2011102579A (ru) 2012-07-27
RU2567100C2 (ru) 2015-10-27
CN107936117A (zh) 2018-04-20
ZA201008593B (en) 2014-02-26
KR20210065201A (ko) 2021-06-03
DK3444274T3 (da) 2021-03-22
US8673310B2 (en) 2014-03-18
US20180371074A1 (en) 2018-12-27
EP3444274A1 (en) 2019-02-20
MX345039B (es) 2017-01-16
EP2307457B1 (en) 2018-06-13
US20140193400A1 (en) 2014-07-10
JP2017051201A (ja) 2017-03-16
KR20190133077A (ko) 2019-11-29
KR102050040B1 (ko) 2019-11-28
PL2307457T5 (pl) 2022-12-27
SI3444274T1 (sl) 2021-04-30
KR101893010B1 (ko) 2018-08-29
US20160251428A1 (en) 2016-09-01
KR101773904B1 (ko) 2017-09-04
US20110159007A1 (en) 2011-06-30
MX2011000075A (es) 2011-03-02
AU2009264564B2 (en) 2014-05-08
PL2307457T3 (pl) 2018-11-30
SI2307457T1 (sl) 2018-11-30
SI2307457T2 (sl) 2022-10-28
PL3444274T3 (pl) 2021-06-14
HUE039692T2 (hu) 2019-01-28
RU2678120C1 (ru) 2019-01-23
BRPI0914319B8 (pt) 2021-05-25
KR20110028516A (ko) 2011-03-18
CA2727992A1 (en) 2009-12-30
ES2687259T5 (es) 2022-10-14
PH12014501962A1 (en) 2015-03-16
RU2653753C1 (ru) 2018-05-14
EP2307457B2 (en) 2022-06-22
EP2307457A2 (en) 2011-04-13
HUE053548T2 (hu) 2021-07-28
US9422366B2 (en) 2016-08-23
CA2727992C (en) 2017-10-17
RU2704838C1 (ru) 2019-10-31
JP2015083607A (ja) 2015-04-30
JP6100463B2 (ja) 2017-03-22
CY1123978T1 (el) 2022-05-27
WO2009155723A3 (en) 2010-04-22
KR20160128439A (ko) 2016-11-07
ES2861592T3 (es) 2021-10-06
CL2010001543A1 (es) 2012-02-03
WO2009155723A2 (en) 2009-12-30
AU2009264564A1 (en) 2009-12-30
US10100111B2 (en) 2018-10-16
US11578123B2 (en) 2023-02-14
EP3444274B1 (en) 2020-12-23
ES2687259T3 (es) 2018-10-24
PT2307457T (pt) 2018-10-16
PH12014501962B1 (en) 2015-03-16
CN107936117B (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
HRP20210357T1 (hr) Stabilna i topljiva protutijela koja inhibiraju tnf
JP7038745B2 (ja) 甲状腺ホルモンアナログ及びその多形体の合成方法
ES2399945T3 (es) Agonistas novedosos de los receptores de glucocorticoides
ES2663878T3 (es) Compuestos que tienen actividad antagonista del receptor muscarínico y actividad agonista del receptor beta-2 adrenérgico
JP6602902B2 (ja) 脾臓チロシンキナーゼｉ（ｓｙｋ）阻害剤としての２−（２−アミノシクロヘキシル）アミノピリミジン−５−カルボキサミド類
WO2020020267A1 (zh) 一种取代的多环性吡啶酮化合物及其前药
TWI374147B (en) Novel 11β-hydroxyandrosta-4-ene-3-ones
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
CN107903389B (zh) E选择素靶向的聚乙二醇两端双修饰抗肿瘤药物的合成及应用
WO2021164677A1 (zh) 一种抗合胞病毒膜融合抑制剂
TW201040196A (en) Novel amide compounds
US20210323971A1 (en) Synthesis methods for upadacitinib and intermediate thereof
JP2016145212A (ja) Ｃｄｄｏエチルエステルの多形体及びその用途
JPWO2021146454A5 (hr)
WO2022258060A1 (zh) 一种lanifibranor的晶型及其制备方法
WO2020181688A1 (zh) 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体
CN109833293A (zh) 一种多索茶碱注射液的制备方法
WO2024140934A1 (zh) 一种连接基药物偶联物的制备方法及其中间体
WO2019001549A1 (zh) 一种多臂单一分子量聚乙二醇及其活性衍生物及其制备和应用
ES2672140T3 (es) Derivados de isoxazolidina
US20190218249A1 (en) A process for purification of carfilzomib intermediate
WO2017199903A1 (ja) キノリン誘導体の結晶
US20190315795A1 (en) Crystalline 3',5'-cyclic diguanylic acid
US20130123197A1 (en) Crystal of Peptide Substance as well as the Preparation Method and Use Thereof
CA3014421C (en) Peptide derivative and use thereof